Shudong Wang
Professor of Medicinal Chemistry
Organisation unit
College of Health
School of Pharmacy and Biomedical Sciences
Contact
About me
Dr. Shudong Wang (Ph.D., MRACI Chartered Chemist, FRSC) is a Professor of Medicinal Chemistry and Head of Drug Discovery and Development at the Adelaide University. Her research focuses on innovative cancer therapies, including target validation, drug discovery, and clinical development. After earning her Ph.D. in 1998, Dr. Wang spent seven years at Cyclacel Inc. (NASDAQGM:CYCC) in the UK, where she served as Head of Chemistry and Oncology Program Manager. During her tenure, she advanced the company’s medicinal chemistry and drug discovery efforts, leading multiple projects to preclinical and clinical stages.
In 2005, she joined the University of Nottingham's School of Pharmacy, UK, as Associate Professor and Reader in Medicinal Chemistry, where she led the development of the first-in-class oral CDK9 inhibitor I-73, now in Phase 2 clinical trials for Acute Myeloid Leukemia (AML).
In December 2011, Professor Wang joined the University of South Australia, where she established the region’s first Drug Discovery and Development Centre. She has led to build capabilities in drug design, medicinal chemistry, cellular & animal pharmacology, and clinical trials. With over 120 patent applications and seven drug candidates, she has an extensive track record in translational research. One of her drug candidates - Auceliciclib has completed Phase 1/2a trials in patients with advanced solid tumors, including brain, pancreatic, liver, colorectal, and ovarian cancers. Professor Wang is highly experienced in the drug development process, including intellectual property protection, clinical trials, regulatory pathways, and commercialization. She has founded two oncology drug companies that are conducting clinical trials with her drug candidates.
As a chief investigator, Professor Wang has secured over $20 million in research grant funding over the past 10 years, including support from NHMRC, ARC, Cancer Council SA, The Foundation for Children, Tour de Cure, and from pharmaceutical companies. She held SA Cancer Council's Principal Cancer Research Fellowship (2013-2017), and received the NHMRC Research Excellence Award in 2017. In April 2024, Professor Wang was appointed as a Member of the MRFF Australian Brain Cancer Mission's first Expert Advisory Panel by the Minister for Health and Aged Care.
Dr. Shudong Wang (Ph.D., MRACI Chartered Chemist, FRSC) is a Professor of Medicinal Chemistry and Head of Drug Discovery and Development at the Adelaide University. Her research focuses on innovative cancer therapies, including target validation, drug discovery, and clinical development. After earning her Ph.D. in 1998, Dr. Wang spent seven years at Cyclacel Inc. (NASDAQGM:CYCC) in the UK, where she served as Head of Chemistry and Oncology Program Manager. During her tenure, she advanced the company’s medicinal chemistry and drug discovery efforts, leading multiple projects to preclinical and clinical stages. In 2005, she joined the University of Nottingham's School of Pharmacy, UK, as Associate Professor and Reader in Medicinal Chemistry, where she led the development of the first-in-class oral CDK9 inhibitor I-73, now in Phase 2 clinical trials for Acute Myeloid Leukemia (AML). In December 2011, Professor Wang joined the University of South Australia, where she established the region’s first Drug Discovery and Development Centre. She has led to build capabilities in drug design, medicinal chemistry, cellular & animal pharmacology, and clinical trials. With over 120 patent applications and seven drug candidates, she has an extensive track record in translational research. One of her drug candidates - Auceliciclib has completed Phase 1/2a trials in patients with advanced solid tumors, including brain, pancreatic, liver, colorectal, and ovarian cancers. Professor Wang is hi...
Read more
Read less
Last updated
on 15/01/2026
by Shudong Wang